Nurix Therapeutics Stock In The News
| NRIX Stock | USD 22.64 0.15 0.66% |
Our overall analysis of Nurix Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Nurix Therapeutics. The specific impact of Nurix Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Nurix Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Nurix Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Nurix Therapeutics Backtesting and Nurix Therapeutics Hype Analysis. For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.
Nurix |
Nurix Therapeutics Today Top News and Investor Outlook
Nurix Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Nurix and other traded companies coverage with news coverage. We help investors stay connected with Nurix headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Nurix Stock performance. Please note that trading solely based on the Nurix Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Nurix Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Nurix earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Nurix Therapeutics that are available to investors today. That information is available publicly through Nurix media outlets and privately through word of mouth or via Nurix internal channels. However, regardless of the origin, that massive amount of Nurix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nurix Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nurix Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nurix Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nurix Therapeutics alpha.
Nurix Largest EPS Surprises
Earnings surprises can significantly impact Nurix Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-07-13 | 2021-05-31 | -0.54 | -0.6 | -0.06 | 11 | ||
2024-07-11 | 2024-05-31 | -0.63 | -0.71 | -0.08 | 12 | ||
2023-10-12 | 2023-08-31 | -0.76 | -0.68 | 0.08 | 10 | ||
2023-02-09 | 2022-11-30 | -0.79 | -0.87 | -0.08 | 10 | ||
2023-07-13 | 2023-05-31 | -0.56 | -0.45 | 0.11 | 19 | ||
2023-04-13 | 2023-02-28 | -0.87 | -0.75 | 0.12 | 13 |
Nurix Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Nurix Therapeutics Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
20th of November 2024
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-59... at finance.yahoo.com
15th of November 2024
Redmile Group, LLC Adjusts Stake in Krystal Biotech Inc at gurufocus.com
7th of November 2024
Subdued Growth No Barrier To Nurix Therapeutics, Inc. With Shares Advancing 25 at simplywall.st
4th of November 2024
Disposition of 3290 shares by Christine Ring of Nurix Therapeutics at 25.0 subject to Rule... at investing.com
1st of November 2024
Nurix therapeutics CFO Hans van Houte sells 86,083 in stock at investing.com
31st of October 2024
Nurix therapeutics CFO Hans van Houte sells 57,554 in stock at investing.com
30th of October 2024
Disposition of 1924 shares by Christine Ring of Nurix Therapeutics subject to Rule 16b-3 at MacroaxisInsider
21st of October 2024
Nurix Therapeutics Announces Presentations atthe 7th Annual TPD Induced Proximity Summit at finance.yahoo.com
18th of October 2024
Acquisition by Kunkel Lori Anne of 25000 shares of Nurix Therapeutics at 16.19 subject to ... at MacroaxisInsider
15th of October 2024
Nurix Therapeutics Given New 26.00 Price Target at Royal Bank of Canada at thelincolnianonline.com
26th of September 2024
Renaissance Technologies LLC Purchases 144,700 Shares of Nurix Therapeutics, Inc. - Market... at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Nurix Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Nurix Therapeutics' short interest history, or implied volatility extrapolated from Nurix Therapeutics options trading.
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.